94 related articles for article (PubMed ID: 11977645)
21. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Amari M; Ishida T; Takeda M; Ohuchi N
Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
23. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
24. Role of capecitabine (Xeloda) in breast cancer.
Kaklamani VG; Gradishar WJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):137-44. PubMed ID: 12722873
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
26. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
[TBL] [Abstract][Full Text] [Related]
27. Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study.
Maisano R; Caristi N; Mare M; Raffaele M; Iorfida M; Mafodda A; Zavettieri M; Nardi M
Anticancer Res; 2007; 27(4C):2871-5. PubMed ID: 17695463
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Lorvidhaya V; Chitapanarux I; Phromratanapongse P; Kamnerdsupaphon P; Tharavichitkul E; Lertsanguansinchai P; Hsieh CY; Sukthomya V
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1271-5. PubMed ID: 20647708
[TBL] [Abstract][Full Text] [Related]
30. [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
Guo L; Lin HX; Li FY; Li Q; Qiu F; Luo DH; Guo X; Hong MH
Zhonghua Zhong Liu Za Zhi; 2004 Apr; 26(4):250-3. PubMed ID: 15312392
[TBL] [Abstract][Full Text] [Related]
31. [Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
Semiglazova TIu; Gershanovich ML
Vopr Onkol; 2001; 47(3):298-302. PubMed ID: 11544827
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
[TBL] [Abstract][Full Text] [Related]
33. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A
Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035
[TBL] [Abstract][Full Text] [Related]
34. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
35. [Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing cisplatin-resistant ovarian tumors].
Makhnova EV; Gershanovich ML
Vopr Onkol; 2003; 49(2):193-7. PubMed ID: 12785204
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study.
Ciuleanu E; Irimie A; Ciuleanu TE; Popita V; Todor N; Ghilezan N
J BUON; 2008; 13(1):37-42. PubMed ID: 18404784
[TBL] [Abstract][Full Text] [Related]
37. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Sternberg CN; Reichardt P; Holland M
Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer.
Gaui MF; Amorim G; Arcuri RA; Pereira G; Moreira D; Djahjah C; Biasoli I; Spector N
Am J Clin Oncol; 2007 Feb; 30(1):78-81. PubMed ID: 17278899
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Wang Y; Yang H; Wei JF; Meng L
Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
